RA
KALV

Rosalind Advisors’s KalVista Pharmaceuticals KALV Stock Holding History

Rosalind Advisors’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-157,725
Closed -$1.78M – 45
2025
Q2 		$1.78M Sell
157,725
-146,139
-48% -$1.79M 0.86% 23
2025
Q1 		$3.51M Hold
303,864
– – 1.71% 21
2024
Q4 		$2.57M Hold
303,864
– – 1.39% 23
2024
Q3 		$3.52M Sell
303,864
-34,121
-10% -$429K 2.33% 16
2024
Q2 		$3.98M Buy
337,985
+50,000
+17% +$584K 3.15% 15
2024
Q1 		$3.42M Sell
287,985
-12,015
-4% -$160K 3.19% 15
2023
Q4 		$3.67M Buy
+300,000
New +$2.73M 3.07% 16

Other funds holding KALV

VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.69B AUM 86.67% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $761B AUM 31.28% 1-Year Est. Return